Cargando…

PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

BACKGROUND: PD‐1 inhibitors are routinely used for the treatment of advanced melanoma. This study sought to determine whether PD‐L1 expression on circulating tumor cells (CTCs) can serve as a predictive biomarker of clinical benefit and response to treatment with the PD‐1 inhibitor pembrolizumab. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khattak, Muhammad A., Reid, Anna, Freeman, James, Pereira, Michelle, McEvoy, Ashleigh, Lo, Johnny, Frank, Markus H., Meniawy, Tarek, Didan, Ali, Spencer, Isaac, Amanuel, Benhur, Millward, Michael, Ziman, Melanie, Gray, Elin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Immuno‐Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066715/ https://www.ncbi.nlm.nih.gov/pubmed/32162809 http://dx.doi.org/10.1634/theoncologist.2019-0557

Ejemplares similares

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma
por: McEvoy, Ashleigh C., et al.
Publicado: (2017)

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma
por: Calapre, Leslie, et al.
Publicado: (2018)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection
por: Marsavela, Gabriela, et al.
Publicado: (2020)

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies
por: McEvoy, Ashleigh C., et al.
Publicado: (2019)

Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells
por: Aya-Bonilla, Carlos Alberto, et al.
Publicado: (2020)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
por: Warburton, Lydia, et al.
Publicado: (2020)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression
por: Marsavela, Gabriela, et al.
Publicado: (2021)

Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
por: Mathias, Kristen, et al.
Publicado: (2023)

Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma
por: Warburton, L., et al.
Publicado: (2020)

Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
por: Clark, Michael E., et al.
Publicado: (2020)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
por: Akamatsu, Hiroaki, et al.
Publicado: (2019)

Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Humoral Immune Response of SARS‐CoV‐2–Infected Patients with Cancer: Influencing Factors and Mechanisms
por: Esperança‐Martins, Miguel, et al.
Publicado: (2021)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection
por: Alkrekshi, Akram, et al.
Publicado: (2021)

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials
por: Wei, Xiao-Li, et al.
Publicado: (2022)

Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
por: Morris, Van K, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience
por: Nardo, Mirella, et al.
Publicado: (2023)

Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center
por: Farha, Natalie, et al.
Publicado: (2023)

Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study
por: Tiu, Bruce C, et al.
Publicado: (2023)

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
por: Aya-Bonilla, Carlos A., et al.
Publicado: (2017)

Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies
por: Calapre, Leslie, et al.
Publicado: (2023)

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Acheampong, Emmanuel, et al.
Publicado: (2020)

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
por: Gray, Elin S., et al.
Publicado: (2015)

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma
por: Klinac, Dragana, et al.
Publicado: (2014)

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
por: Acheampong, Emmanuel, et al.
Publicado: (2019)

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells
por: Freeman, James B, et al.
Publicado: (2012)

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles
por: Aya-Bonilla, Carlos, et al.
Publicado: (2019)

Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients
por: Asante, Du-Bois, et al.
Publicado: (2021)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
por: Dart, Sarah J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_28jr5od27jjika82m9roisk6bd